ArticleMayo Clinic proceedings2011
Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.
Article in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 88 citations in OpenAlex.
- Intervention to improve the quality of antimicrobial prescribing for urinary tract infection: a cluster randomized trial.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Trial
- The sublingual vaccine MV140 is dominant over prophylactic antibiotics for the prevention of recurrent, uncomplicated urinary tract infections in adult women A cost-utility analysis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- A systematic review and meta-analysis on prevalence and antimicrobial resistance profile ofHeliyon · 2023Review
- Antimicrobial Susceptibility of Community-Acquired Urine Bacterial Isolates in French Amazonia.The American journal of tropical medicine and hygiene · 2023Article
- Empiric versus culture-based antibiotic therapy for UTIs in menopausal women.World journal of urology · 2023Article
- ESBL-Positive Enterobacteriaceae from Dogs of Santiago and Boa Vista Islands, Cape Verde: A Public Health Concern.Antibiotics (Basel, Switzerland) · 2023Article
- Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review.Frontiers in cellular and infection microbiology · 2023Review
- Article
- Article
- Fosfomycin and nitrofurantoin: classic antibiotics and perspectives.The Journal of antibiotics · 2021Review
- Change-points in antibiotic consumption in the community, European Union/European Economic Area, 1997-2017.The Journal of antimicrobial chemotherapy · 2021Review
- Genomics and Virulence ofMicroorganisms · 2021Article
- Metabolites Potentiate Nitrofurans in Nongrowing Escherichia coli.Antimicrobial agents and chemotherapy · 2021Article
- Clinical Efficacy and Cost Analysis of Antibiotics for Treatment of Uncomplicated Urinary Tract Infections in the Emergency Department of a Tertiary Hospital in Saudi Arabia.Therapeutics and clinical risk management · 2021Article
- A guide for urogynecologic patient care utilizing telemedicine during the COVID-19 pandemic: review of existing evidence.International urogynecology journal · 2020Review
- Comparison of Escherichia coli antibiotic-resistance profiles and incidence of betalactamase phenotypes in three private health facilities in PerúBiomedica : revista del Instituto Nacional de Salud · 2020Article
- Surveillance of antibiotic resistance among uropathogens in Aljouf region northern Saudi Arabia.Iranian journal of microbiology · 2019Article
- The IOU Consensus Recommendations for Empirical Therapy of Cystitis in Nursing Home Residents.Journal of the American Geriatrics Society · 2019Article
- Membrane-Active Hydantoin Derivatives as Antibiotic Agents.Journal of medicinal chemistry · 2017Article
- Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics.BJGP open · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo analyze the costs of nitrofurantoin use compared to those of other antibiotics recommended for treatment of uncomplicated urinary tract infection (UTI). PATIENTS AND
methodsWe used a decision analysis model to perform cost-minimization and sensitivity analyses to determine the level of trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolone resistance that would favor the use of nitrofurantoin as a first-line empirical treatment of uncomplicated UTIs. The model used a program perspective to evaluate costs.
resultsNitrofurantoin was cost-minimizing when the prevalence of fluoroquinolone resistance exceeded 12% among uropathogens or the prevalence of TMP-SMX resistance exceeded 17%. On 2-way sensitivity analysis, variables that had a significant impact on our cost-minimization threshold included cost of antibiotics and probability of clinical cure with antibiotics.
conclusionFrom a payer perspective, nitrofurantoin appears to be a reasonable alternative to TMP-SMX and fluoroquinolones for empirical treatment of uncomplicated UTIs, especially given the current prevalence of antibiotic resistance among community uropathogens. On the basis of efficacy, cost, and low impact on promoting antimicrobial resistance, clinicians should consider nitrofurantoin as a reasonable alternative to TMP-SMX and fluoroquinolones for first-line therapy for uncomplicated UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.